srch

Blueprint Medicines (Switzerland) GmbH. Swiss Biotech Association ... https://www.blueprintmedicines.com/. Location. Baarerstrasse 8, 6300 Zug, Switzerland.

See insights on Blueprint Medicines including office locations, competitors, ... Blueprint Medicines has offices in Cambridge, Amsterdam, Lugano and Zug.

02.09.2021 · Blueprint Medicines has 383 employees across 5 locations and $793.74 M in annual revenue in FY 2020. See insights on Blueprint Medicines including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.

Job Description Senior Director, Pricing & Market Access, International Zug, CH At Blueprint Medicines, we are creating a blueprint for the future of healthcare – embracing a personalized medicine revolution by focusing on delivering new medicines that are targeted to the genetic driver of disease.

Blueprint Medicines (Switzerland) GmbH in Zug ✓ aktiv ✓ Gegründet 2018 ✓ Management: Georg Meyer u.a ✓ Letzte Änderung: 10.12.2021.

Das Unternehmen Blueprint Medicines (Switzerland) GmbH ist eine GmbH mit Sitz in Zug, im Kanton Zug, die im Jahr 2018 gegründet wurde.

Company Description: Blueprint Medicines (Switzerland) GmbH is located in Zug, ZUG, Switzerland and is part of the Scientific Research and Development ...

Blueprint Medicines Zug (Switzerland) employees haven't posted any photos yet. Get this page going by posting a photo. It only takes a second, and your photos ...

Location: Zug (Switzerland) or Paris (France), Munich (Germany) Start Date: Asap At Blueprint Medicines, as our name indicates, we are creating a blueprint for the future of healthcare. We are a leading company in the personalized medicine revolution by focusing on delivering new medicines that are targeted to the genetic driver of disease.

GAVRETO is jointly commercialized in the U.S. by Blueprint Medicines and Genentech, a wholly owned member of the Roche Group, under Blueprint Medicines’ collaboration with Roche.

Blueprint Medicines Appoints Daniella Beckman to its Board of Directors Dec 07, 2021 Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) More News Events and presentations Nov 29, 2021 Blueprint Medicines Conference Call Oct 28, 2021 Q3 2021 Blueprint Medicines Corp Conference Call More events and presentations

Blueprint Medicines is a global precision therapy company that invents life-changing therapies for people with cancer and hematologic disorders. We create medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Since 2011, we have leveraged our research platform, including expertise ...

Blueprint Medicines Global Headquarters. 45 Sidney Street. Cambridge, MA 02139. (617) 374-7580. info@blueprintmedicines.com. EU Office. Blueprint Medicines (Switzerland) GmbH. Baarerstrasse 8. 6300 Zug.

Blueprint Medicines | 23408 followers on LinkedIn. Staying one step ahead of disease | Blueprint Medicines is a global ... Baarerstrasse 8. Zug, CH.

Blueprint Medicines (Switzerland) GmbH is a Limited Liability Company based in Zug, in the canton of Zug, founded in 2018. Its identification number UID is CHE-499.149.707. It is active in "other research and experimental development on natural sciences and engineering".

Zug, Switzerland Blueprint Medicines is a global precision therapy company that invents life-changing therapies for people with cancer and hematologic disorders. Applying an approach that is both precise and agile, we create medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease.

45 Sidney Street Cambridge, MA 02139 (617) 374-7580 info@blueprintmedicines.com. EU Office Blueprint Medicines (Switzerland) GmbH. Baarerstrasse 8 6300 Zug

We aim to connect the worlds of drug discovery, clinical development and commercialization to deliver a new generation of potent, selective medicines. A uniquely targeted, scalable approach. By focusing on genomic drivers of disease, we aim to identify the people most likely to respond to our therapies, increase efficiency during clinical ...